You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 65 No. 6, June 1961 TABLE OF CONTENTS
  Archives
  •  Online Features
  ARTICLES
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on HighWire
 •Citing articles on Web of Science (3)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Enzymatic Zonulolysis as an Aid in Cataract Surgery

A Follow-Up Report on 432 Cases with 491 Additional Cases

PATRICK J. KENNEDY, M.D.; JAMES S. JORDAN, M.D.; JOSEPH F. MORRISON, M.D.; ROBERT D. MULBERGER, M.D.; STANLEY W. BOLAND, M.D.

Arch Ophthalmol. 1961;65(6):801-804.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

One year ago we reported 432 cases of cataract extraction in which {alpha}-chymotrypsin was used to aid in zonulolysis.1 We are now reporting its use in 491 additional cases performed by the same authors in the same institutions. Eighty-eight of these were performed by the resident surgeons of Wills Eye Hospital under close supervision. Our results have again been tabulated according to the questionnaire on {alpha}-chymotrypsin suggested by the Committee on Alpha-Chymotrypsin of the American Academy of Ophthalmology and Otolaryngology.

The following 4 preparations of {alpha}-chymotrypsin were used:

1. Alpha Chymar (Armour Laboratories, Kankakee, Ill.)

2. Quimotrase (PEVYA Laboratories, Barcelona, Spain)

3. Zolyse (Alcon Laboratories, Fort Worth, Texas)

4. Chymexon (Schieffelin and Co., New York)

We were not aware of any difference in the action of these products. We have agreed on a 1:5,000 solution because we believe this concentration assures us of the best result. We have not . . . [Full Text PDF of this Article]


Author Affiliations

Upper Darby, Pa.; Scranton, Pa.; Wilkes-Barre, Pa.; Philadelphia, Pa.; Scranton, Pa.


Footnotes

Submitted for publication Feb. 10, 1961.

Presented at the Thirteenth Annual Clinical Conference of the Wills Eye Hospital, Feb. 10, 1961.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1961 American Medical Association. All Rights Reserved.